Search the Newsreel

4D Molecular Therapeutics (FDMT) posts $141.7M first-half 2026 net loss

FDMT (NASDAQ: FDMT) stockholder schedules 1,635-share sale after option exercise

A stockholder of 4D Molecular Therapeutics, Inc. (FDMT) has filed to sell 1,635 common shares on NASDAQ, to be issued through the exercise of stock options for cash on August 13, 2026. This filing also discloses previous Rule 10b5-1 plan sales by Scott Bizily …

4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

4D Molecular Therapeutics (4DMT) reported its Q2 2026 financial results, highlighting significant progress in its clinical programs for wet AMD and DME, including completed enrollment for two Phase 3 trials for 4D-150 and strong two-year data from its PRISM Phase 2b study. The company …

4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates

4D Molecular Therapeutics, Inc. (FDMT) reported a Q2 loss of $1.04 per share, matching Zacks Consensus Estimate, but surpassed revenue estimates significantly with $3.78 million, beating expectations by 142.37%. The company's stock has performed well year-to-date, rising 58.3% against the S&P 500's 13.2% gain, …

Dimensional Fund Advisors LP Purchases 227,982 Shares of 4D Molecular Therapeutics, Inc. $FDMT

Dimensional Fund Advisors LP has increased its stake in 4D Molecular Therapeutics (NASDAQ:FDMT) by 77.3%, purchasing an additional 227,982 shares to bring its total ownership to 522,823 shares, representing 1.0% of the company. Institutional investors now own 99.27% of the stock, while company insiders …

4D Molecular Therapeutics Inc (FDMT) Stock News Today

This article provides current stock information for 4D Molecular Therapeutics Inc (FDMT), noting its recent price dip. It states that more news regarding FDMT's earnings, analyst ratings, and key developments will be available soon. The page serves as a hub for investors to track …

4D Molecular Therapeutics Inc (FDMT) Earnings Forecast: Future EPS & Revenue Growth Estimates

4D Molecular Therapeutics Inc expected to post a loss of $1.02 a share - Earnings Preview

4D Molecular Therapeutics Inc (FDMT) is projected to report a loss of $1.02 per share in its upcoming earnings announcement. This information comes from a Refinitiv earnings preview. The article provides a brief outlook on the company's expected financial performance.

4D Molecular Therapeutics, Inc. (FDMT) Stock Price, News, Quote & History

This Yahoo Finance page provides comprehensive financial information for 4D Molecular Therapeutics, Inc. (FDMT), a late-stage biotechnology company. It includes real-time stock price, historical data, performance metrics against the S&P 500, analyst ratings,

4D Molecular Therapeutics, Inc. (FDMT) insider sells 26,842 shares under plan

David Kirn, a director and officer at 4D Molecular Therapeutics, Inc. (FDMT), sold 26,842 shares of common stock on August 4, 2026, at a weighted average price of $10.2301 per share. This transaction was conducted under a 10b5-1 trading plan established on January 9, …

Ken Fisher's 4D Molecular Therapeutics Inc(FDMT) Holding History

This article details Ken Fisher's investment in 4D Molecular Therapeutics Inc (FDMT), held through Fisher Asset Management, LLC. As of June 30, 2026, he owns 65,751 shares valued at $874,490, representing 0% of his portfolio. Fisher has made one purchase of FDMT at an …

Form 144 4D Molecular Therapeutics For: 4 August By Investing.com

This article from Investing.com announces a Form 144 filing for 4D Molecular Therapeutics (FDMT) on August 4th. The content is brief, primarily serving as a placeholder for the filing information and is surrounded by typical financial news website navigation and market data. The article …

4D Molecular Therapeutics (FDMT) Insider David Kirn Sells 12,415 Shares

David Kirn, an insider at 4D Molecular Therapeutics (FDMT), sold 12,415 shares, bringing his total sales over the past year to 187,416 shares with no purchases. This selling activity, coupled with a lack of insider buying and a significant discount to the GuruFocus Value, …

FDMT (FDMT) insider plans 26,842-share Class A sale after sizable prior trades

An insider at 4D Molecular Therapeutics, Inc. (FDMT) plans to sell 26,842 Class A shares, valued at approximately $275,398.92, through Goldman Sachs & Co. LLC on or about August 4, 2026. These shares were originally acquired in a private transaction on December 15, 2020. …

4D Molecular Therapeutics (FDMT) CEO sells 12,415 shares via 10b5-1 plan

David Kirn, President and CEO of 4D Molecular Therapeutics (FDMT), sold 12,415 shares of company stock on August 3, 2026, at a weighted average price of $10.0461 per share. This transaction was conducted under a pre-arranged 10b5-1 trading plan adopted on January 9, 2026. …

4D Molecular Therapeutics (FDMT) to Announce Earnings on Monday

4D Molecular Therapeutics (FDMT) is set to release its Q2 2026 earnings before market open on Monday, August 10th, with analysts expecting a loss of $1.04 per share and revenue of $3.62 million. The company's shares have recently declined by 3.3%, and the stock …

FDMT (FDMT) investor David Kirn plans Rule 144 sale of 12,415 shares

David Kirn, a shareholder in 4D Molecular Therapeutics, Inc. (FDMT), has filed a Rule 144 notice to sell 12,415 shares of Class A Common Stock through Goldman Sachs & Co. LLC on or after August 3, 2026. The proposed sale has an aggregate market …

Enterprise value to EBIT forward of 4D Molecular Therapeutics, Inc. – NASDAQ:FDMT

The article provides a financial metric, "Enterprise value to EBIT forward," for 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT). This information is sourced from TradingView, which offers various financial data and tools for market analysis. The content primarily focuses on presenting this specific financial ratio …

B. Riley Initiates 4D Molecular Therapeutics at Buy With $37 Price Target

B. Riley has initiated coverage on 4D Molecular Therapeutics (FDMT) with a "Buy" rating and a price target of $37. The company, a late-stage biotechnology firm, is advancing several therapeutic candidates, including 4D-150 for wet age-related macular degeneration and diabetic macular edema, and 4D-710 …

B.Riley initiates 4D Molecular Therapeutics stock coverage with buy rating

B.Riley has initiated coverage on 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy rating and a price target of $37.00, suggesting substantial upside from its current price and indicating it may be undervalued. The firm views the company's lead candidate, 4D-150, for neovascular AMD as …

FDMT|4D Molecular Therapeutics Inc|Price:10.060|Chg%:+0.450

This analysis of 4D Molecular Therapeutics Inc (FDMT) highlights its strong fundamentals, high growth potential, and fair valuation, with a "Buy" rating from multiple analysts and a target price of $28.22. The company, a late-stage biotechnology firm, is advancing therapies for retinal vascular diseases …

4D Molecular Therapeutics Inc (FDMT) Financial Health: Profitability & Balance Sheet Analysis

4D Molecular Therapeutics Inc (FDMT) has a stable financial status with a financial score of 7.34, ranking 132nd in its industry. The company reported a significant year-over-year revenue increase of 21664.29% to $3.05M and a net profit increase of 43.33%. However, its operational efficiency …

4D Molecular Therapeutics, Inc. Revenue Breakdown – NASDAQ:FDMT

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) generated $85.21 million USD in revenue last year, primarily from its Disease-targeted Therapeutics segment. The company's largest contribution by country came from Japan, accounting for $85.00 million USD. This represents a significant increase from the previous year's revenue …

4D Molecular Therapeutics Inc (FDMT) Income Statement

This article provides the quarterly and annual income statements for 4D Molecular Therapeutics Inc (FDMT), detailing key financial metrics such as total revenue, operating expenses, operating profit, and net income. It also includes an FAQ section explaining how to read the income statement, the …

4D Molecular Therapeutics Inc (FDMT) Cash Flow

This article provides a detailed cash flow statement for 4D Molecular Therapeutics Inc (FDMT), covering quarterly and annual data for operating, investing, and financing activities. It presents key financial figures including operating cash flow, net income, capital expenditures, and free cash flow over several …

4D Molecular Therapeutics Inc (FDMT) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical dividend and stock split information for 4D Molecular Therapeutics Inc (FDMT). It states that the company has not distributed any dividends over the past five years. The page also shows FDMT's current stock price, market cap, and other financial overview …

4D Molecular Therapeutics (FDMT) Short Interest & Short Float | Updated Jul 2026

This article provides an updated overview of 4D Molecular Therapeutics (FDMT) short interest data as of July 15, 2026. The company had 11.36 million shares sold short, representing 23.60% of its public float, which is a 14.59% decrease from the previous report. The short …

H.C. Wainwright Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $36

H.C. Wainwright has reiterated its Buy rating for 4D Molecular Therapeutics (FDMT.US), keeping the target price at $36. This indicates continued analyst confidence in the company's financial prospects and stock performance.

4D Molecular Therapeutics Posts Strong 4D-150 Trial Results

4D Molecular Therapeutics announced positive two-year results from its PRISM Phase 2b clinical trial for 4D-150, a treatment for wet age-related macular degeneration. The study demonstrated consistent visual acuity, controlled central subfield thickness, and a significant reduction in treatment burden. The drug was well-tolerated …

4D Molecular releases phase 2 data for wet AMD asset 4D-150

The article reports that 4D Molecular Therapeutics has released Phase 2 data for its wet AMD treatment, 4D-150. This announcement is significant for the company and investors, as it provides an update on the drug's efficacy and safety profile in a clinical setting.

4D Molecular Therapeutics Reports 2-Year Durability Data for 4D-150 in Wet AMD

4D Molecular Therapeutics reported positive 2-year durability data for its gene therapy 4D-150 in patients with Wet AMD from the PRISM Phase 2b trial. This data is critical for validating the "one-and-done" premise of gene therapy, especially as it forms the basis for two …

4D Molecular Therapeutics (Nasdaq: FDMT) posts positive 2-year wet AMD data

4D Molecular Therapeutics (Nasdaq: FDMT) announced positive 2-year data from its PRISM Phase 2b clinical trial for 4D-150 in treating wet age-related macular degeneration (wet AMD). The data, with a cutoff of May 18, 2026, highlighted consistent maintenance of visual acuity and central subfield …

H.C. Wainwright reiterates Buy on 4D Molecular stock on trial data

H.C. Wainwright reiterated a Buy rating and a $36.00 price target on 4D Molecular Therapeutics (NASDAQ:FDMT) after positive two-year data from the company's Phase 2b PRISM trial was presented. The trial, evaluating gene therapy candidate 4D-150 for wet age-related macular degeneration, showed consistent visual …